title: Sorafenib is active on lung metastases from synovial sarcoma.
authors.forename: U
authors.initials: U
authors.lastname: Basso
authors.forename: A
authors.initials: A
authors.lastname: Brunello
authors.forename: A
authors.initials: A
authors.lastname: Bertuzzi
authors.forename: A
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000000981:diagnostic imaging / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D011859:Radiography; D013584:Sarcoma, Synovial / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D000077157:Sorafenib; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib